As a part of an effort to understand what health issues might be particular to people in the Nevada region, The Healthy Nevada Project is planning to sequence the DNA of 40,000 Nevadans.
The advancement of sequencing technology has had the singe biggest effect on genomics research. As it develops further, so does the scope of genomic research and applications.
When a hepatitis C treatment called Harvoni was released in 2014, Dr. Ronald Cirillo knew it was a big deal.
Thermo Fisher Scientific and Illumina have announced a commercial agreement that enables Illumina to sell Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing platforms.
Thermo Fisher Scientific Announce New NGS Technology to Enable Clinical Research in Liquid Biopsy and Immuno-Oncology
Thermo Fisher Scientific has expanded its Oncomine portfolio with new assays for liquid biopsy and immuno-oncology to complement its comprehensive solutions for clinical research
Thermo Fisher Scientific Introduces Ion GeneStudio S5 Series, A Line of Highly Versatile Next Generation Sequencers
Thermo Fisher Scientific announces the Ion GeneStudio S5 Series, a new line of benchtop NGS instruments that provide unmatched flexibility and scalability enabled by five Ion S5 chips, including the new Ion 550 chip, to facilitate wide-ranging experiments on a single platform.
To kick off the JP Morgan Healthcare Conference, Edico Genome and Genomics England announced a new partnership to strengthen the accuracy and consistency of next-generation sequencing (NGS) data analysis in Genomics England’s Rare Disease Pilot.
The Rady Children’s Institute for Genomic Medicine (RCIGM) announced Wednesday the recruitment of six influential science researchers to serve on the Institute’s inaugural Scientific Advisory Board (SAB).
23andMe have announced a large-scale study designed to uncover the genetic reasons why people respond differently to diet and exercise regimes.
Targeted RNA sequencing is being hailed as a major growth area up to 2024. It is hotly expected that new RNAseq applications will be developed by the growing next-generation sequencing users community.
Oxford Nanopore’s palm-sized MiniON sequencer has been paired up with a DNA replicator that’s able to amplify genetic samples through PCR in space.
Roughly 3% of the population have drug receptors that are so genetically different, they are more likely to have altered or adverse reactions to medicines.